Patients with Mild Cognitive Impairment May be Stratified by Advanced Diffusion Metrics and Neurocognitive Testing

BACKGROUND AND PURPOSEMild cognitive impairment (MCI) is a prevalent disorder, with a subset of patients progressing to dementia each year. Although MCI may be subdivided into amnestic or vascular types as well as into single or multiple cognitive domain involvement, most prior studies using advanced diffusion imaging have not accounted for these categories. The purpose of the current study was to determine if the pattern of diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI) metrics in patients with amnestic MCI (aMCI) correlate to specific cognitive domain impairments.METHODSNineteen consecutive patients with aMCI referred for brain magnetic resonance imaging (MRI) were included. All subjects underwent neurocognitive testing. A z‐score was calculated for each domain and a composite of all four domains. Brain MRI included standard structural imaging and diffusion imaging. Volumetric, DTI, and DKI metrics were calculated and statistical analysis was performed with adjustments for multiple measures and comparisons.RESULTSStatistically significant correlations between diffusion metrics and cognitive z‐scores were detected: visuospatial‐visuoconstructional z‐scores only correlated with alterations in the corpus callosum splenium, executive functioning z‐scores with the corpus callosum genu, memory testing z‐scores with the left hippocampus, and composite z‐scores with the anterior centrum semiovale.CONCLUSIONNeuroimaging studies of patients with aMCI to date have assumed a population with homogeneous cognitive impairment. Our results demonstrate selective patterns of regional diffusion metric alterations correlate to specific cognitive domain impairments. Future studies should account for this heterogeneity, and this may also be useful for prognostication.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/147217/1/jon12588_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/147217/2/jon12588.pd

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.

BACKGROUND: Five modifiable risk factors are associated with cardiovascular disease and death from any cause. Studies using individual-level data to evaluate the regional and sex-specific prevalence of the risk factors and their effect on these outcomes are lacking. METHODS: We pooled and harmonized individual-level data from 112 cohort studies conducted in 34 countries and 8 geographic regions participating in the Global Cardiovascular Risk Consortium. We examined associations between the risk factors (body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes) and incident cardiovascular disease and death from any cause using Cox regression analyses, stratified according to geographic region, age, and sex. Population-attributable fractions were estimated for the 10-year incidence of cardiovascular disease and 10-year all-cause mortality. RESULTS: Among 1,518,028 participants (54.1% of whom were women) with a median age of 54.4 years, regional variations in the prevalence of the five modifiable risk factors were noted. Incident cardiovascular disease occurred in 80,596 participants during a median follow-up of 7.3 years (maximum, 47.3), and 177,369 participants died during a median follow-up of 8.7 years (maximum, 47.6). For all five risk factors combined, the aggregate global population-attributable fraction of the 10-year incidence of cardiovascular disease was 57.2% (95% confidence interval [CI], 52.4 to 62.1) among women and 52.6% (95% CI, 49.0 to 56.1) among men, and the corresponding values for 10-year all-cause mortality were 22.2% (95% CI, 16.8 to 27.5) and 19.1% (95% CI, 14.6 to 23.6). Harmonized individual-level data from a global cohort showed that 57.2% and 52.6% of cases of incident cardiovascular disease among women and men, respectively, and 22.2% and 19.1% of deaths from any cause among women and men, respectively, may be attributable to five modifiable risk factors. (Funded by the German Center for Cardiovascular Research (DZHK); ClinicalTrials.gov number, NCT05466825.)